MedPath

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)

Phase 3
Active, not recruiting
Conditions
Relapsing Multiple Sclerosis
Interventions
Registration Number
NCT04586010
Lead Sponsor
Hoffmann-La Roche
Brief Summary

A study to evaluate the efficacy and safety of fenebrutinib on disability progression and relapse rate in adult participants with RMS. Eligible participants will be randomized 1:1 to either fenebrutinib or teriflunomide. At the end of the DBT phase (after disclosure of the DBT results), the Sponsor will determine whether or not to initiate the open-label extension phase of the study.

Detailed Description

Not available

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
746
Inclusion Criteria
  • Expanded Disability Status Scale (EDSS) score of 0 - 5.5 at screening.
  • A diagnosis of RMS in accordance with the revised 2017 McDonald Criteria.
  • Ability to complete the 9-Hole Peg Test (9-HPT) for each hand in < 240 seconds.
  • Ability to perform the Timed 25-Foot Walk Test (T25FWT) in <150 seconds.
  • For female participants of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and refrain from donating eggs.
  • For male participants: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and refrain from donating sperm.

OLE Inclusion Criteria:

  • Completed the Double-Blind Treatment (DBT) phase of the study (remaining on study treatment; no other Disease-Modifying Therapy (DMT) administered) and who, in the opinion of the investigator, may benefit from treatment with fenebrutinib.
  • Participants randomized to the teriflunomide treatment arm during the DBT phase must undergo the accelerated teriflunomide elimination procedure (ATEP) prior to the first administration of open-label fenebrutinib.
  • For female participants of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and refrain from donating eggs.
  • For male participants: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and refrain from donating sperm.
Exclusion Criteria
  • Disease duration of > 10 years from the onset of symptoms and an EDSS score at screening < 2.0.
  • Female participants who are pregnant or breastfeeding, or intending to become pregnant.
  • Male participants who intend to father a child during the study.
  • A diagnosis of primary progressive MS (PPMS) or non-active secondary progressive MS (SPMS).
  • Any known or suspected active infection at screening, including but not limited to a positive screening test for Hepatitis B and C, an active or latent or inadequately treated infection with tuberculosis (TB), a confirmed or suspected progressive multifocal leukoencephalopathy (PML).
  • History of cancer including hematologic malignancy and solid tumors within 10 years of screening.
  • Known presence of other neurological disorders, that could interfere with the diagnosis of MS or assessments of efficacy or safety during the study and clinically significant cardiovascular, psychiatric, pulmonary, renal, hepatic, endocrine, metabolic or gastrointestinal disease.
  • Rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption.
  • Hypoproteinemia.
  • Acute liver disease
  • Chronic liver disease unless considered stable for > 6 months.
  • Presence of cirrhosis (Child-Pugh Class A, B, or C) or Gilbert's Syndrome.
  • Participants with significantly impaired bone marrow function or significant anemia, leukopenia, neutropenia or thrombocytopenia.
  • Any concomitant disease that may require chronic treatment with systemic corticosteroids or immunosuppressants during the course of the study.
  • History of alcohol or other drug abuse within 12 months prior to screening.
  • History of or currently active primary or secondary (non-drug-related) immunodeficiency, including known history of human immunodeficiency virus (HIV) infection.
  • Inability to complete an MRI scan.
  • Adrenocorticotropic hormone or systemic corticosteroid therapy within 4 weeks prior to screening (inhaled and topical corticosteroids are allowed).
  • Receipt of a live-attenuated vaccine within 6 weeks prior to randomization.
  • Any previous treatment with immunomodulatory or immunosuppressive medication without an appropriate washout period.

OLE Exclusion Criteria:

  • Acute liver disease
  • Chronic liver disease unless considered stable for > 6 months

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
FenebrutinibFenebrutinibParticipants will receive oral fenebrutinib with teriflunomide-matching placebo.
FenebrutinibPlaceboParticipants will receive oral fenebrutinib with teriflunomide-matching placebo.
TeriflunomideTeriflunomideParticipants will receive oral teriflunomide with fenebrutinib-matching placebo in a blinded fashion.
TeriflunomidePlaceboParticipants will receive oral teriflunomide with fenebrutinib-matching placebo in a blinded fashion.
Primary Outcome Measures
NameTimeMethod
Annualized Relapse Rate (ARR)Minimum of 96 weeks
Secondary Outcome Measures
NameTimeMethod
Time to Onset of Composite 12-week Confirmed Disability Progression (cCDP12)Minimum of 96 weeks
Time to Onset of Composite 24-week Confirmed Disability Progression (cCDP24)Minimum of 96 weeks
Time to Onset of 12-week Confirmed Disability Progression (CDP12)Minimum of 96 weeks
Time to Onset of 24-week Confirmed Disability Progression (CDP24)Minimum of 96 weeks
Total Number of T1 Gadolinium Enhancing (Gd+) Lesions, New and/or Enlarging T2-weighted Lesions as Detected by Magnetic Resonance Imaging (MRI)Baseline, Weeks 12, 24, 48 and 96
Percentage Change in Total Brain Volume from Week 24 as Assessed by MRIFrom Week 24 to Week 96
Change in Participant-Reported Physical Impacts of Multiple Sclerosis (MS) Measured by the Multiple Sclerosis, 29-Item [MSIS-29] Physical ScaleBaseline, Weeks 12, 24, 36, 48, 60, 72, 84 and 96

The MSIS-29, Version 2 is a 29-item patient-reported measure of the physical and psychological impacts of MS. Participants are asked to rate how much their functioning and well-being has been impacted over the past 14 days on a 4-point scale, from "Not at all" (1) to "Extremely" (4). The physical score is the sum of items 1-20, which is then transformed to a 0-100 scale. The psychological score is the sum of items 21-29, transformed to a 0-100 scale. Higher scores indicate a greater impact of MS.

Time to Onset of 12-week Confirmed 4-point worsening in Symbol Digit Modality Test (SDMT) ScoreMinimum of 96 weeks

The SDMT is used for detecting the presence of cognitive impairment and changes in cognitive functioning over time and in response to treatment. The SDMT is brief, is easy to administer test, and involves a simple substitution task. Using a reference key, the examinee has 90 seconds to pair specific numbers with given geometric figures. Responses will be collected only orally, and administration time is approximately 5 minutes. The number of correct responses in 90 seconds will be considered the SDMT score. A decrease by 4 points on the SDMT score from baseline represents a clinically meaningful change in cognitive processing. The SDMT score ranges from 0 to 110. The higher the results, the better processing speed/working memory.

Change from Baseline to Week 48 in the Concentration of Blood Neurofilament Light Chain (NfL)Up to 48 weeks
Percentage of Participants with Adverse Events (AEs)Up to 4.5 years
Plasma Concentrations of Fenebrutinib at Specified TimepointsUp to 4.5 years
Time to Onset of Composite 12-week Confirmed Progression Independent of Relapse Activity (cPIRA12)Minimum of 96 weeks

Trial Locations

Locations (160)

Inselspital Bern Medizin Neurologie

🇨🇭

Bern, Switzerland

Ospedale Regionale di Lugano - Civico

🇨🇭

Lugano, Switzerland

Hopital Razi

🇹🇳

Mannouba, Tunisia

Fattouma Bourguiba Hospital

🇹🇳

Monastir, Tunisia

Hospital Habib Bourguiba

🇹🇳

Sfax, Tunisia

MNE Lviv Territorial Medical Association Clinical Hospital for Palliative Care

🇺🇦

Lviv, Chernihiv Governorate, Ukraine

Medical Center Dopomoga Plus

🇺🇦

Kyiv, Katerynoslav Governorate, Ukraine

LCC "Medical center "Unimed"

🇺🇦

Zaporizhia, Katerynoslav Governorate, Ukraine

Municipal Non-profit Enterprise Zaporizhzhya Regional Hospital Zaporizhzhya Regional Council

🇺🇦

Zaporizhzhia, Katerynoslav Governorate, Ukraine

SI USSRI of Medical and Social Problems of Disabilities of MOHU

🇺🇦

Dnipro, KIEV Governorate, Ukraine

Medical Center of Private Execution First Private Clinic

🇺🇦

Kyiv, KIEV Governorate, Ukraine

Salutem Medical Center

🇺🇦

Vinnytsia, KIEV Governorate, Ukraine

Medical Clinical Research Center of Medical Center LLC Health Clinic

🇺🇦

Vinnytsi, Podolia Governorate, Ukraine

Separated structural unit ?University hospital? of Dnipro State Medical University

🇺🇦

Dnipro, Tavria Okruha, Ukraine

Studienzentrum Nordwest Dr med Joachim Springub Herr Wolfgang Schwarz

🇩🇪

Westerstede, Germany

University of Alabama Birmingham

🇺🇸

Birmingham, Alabama, United States

Alabama Neurology Associates

🇺🇸

Homewood, Alabama, United States

Center for Neurology and Spine - Phoenix - Hunt - PPDS

🇺🇸

Phoenix, Arizona, United States

Profound Research, LLC

🇺🇸

Carlsbad, California, United States

University of California Irvine

🇺🇸

Irvine, California, United States

SC3 Research Group, Inc

🇺🇸

Pasadena, California, United States

University of Colorado Denver

🇺🇸

Aurora, Colorado, United States

Mountain View Clinical Research

🇺🇸

Denver, Colorado, United States

Advanced Neurology of Colorado, LLC

🇺🇸

Fort Collins, Colorado, United States

Neurology Associates, PA; Research Department

🇺🇸

Maitland, Florida, United States

NorthShore University HealthSystem

🇺🇸

Highland Park, Illinois, United States

Fort Wayne Neurological Center

🇺🇸

Fort Wayne, Indiana, United States

The NeuroMedical Center

🇺🇸

Baton Rouge, Louisiana, United States

Ochsner LSU Health

🇺🇸

Shreveport, Louisiana, United States

Johns Hopkins University School Of Medicine; Outpatient Center

🇺🇸

Baltimore, Maryland, United States

University of Massachusetts Medical School

🇺🇸

Worcester, Massachusetts, United States

Henry Ford Health System

🇺🇸

Detroit, Michigan, United States

Washington University School of Medicine

🇺🇸

Saint Louis, Missouri, United States

Holy Name Hospital; Institute For Clinical Research

🇺🇸

Teaneck, New Jersey, United States

University of New Mexico; MS Specialty Clinic

🇺🇸

Albuquerque, New Mexico, United States

Miami Valley Hospital South; Dayton Physician's Office

🇺🇸

Centerville, Ohio, United States

OhioHealth

🇺🇸

Columbus, Ohio, United States

The Boster Center for MS

🇺🇸

Columbus, Ohio, United States

Oklahoma Medical Research Foundation; MS Center of Excellence

🇺🇸

Oklahoma City, Oklahoma, United States

St. Luke's University Health network

🇺🇸

Bethlehem, Pennsylvania, United States

Premier Neurology

🇺🇸

Greenville, South Carolina, United States

New Orleans Center for Clinical Research

🇺🇸

Knoxville, Tennessee, United States

North Texas Institute of Neurology and Headache NextStage Clinical Research Clinic

🇺🇸

Plano, Texas, United States

Texas Institute for Neurological Disorders

🇺🇸

Sherman, Texas, United States

Multiple Sclerosis Center of Greater Washington

🇺🇸

Vienna, Virginia, United States

Evergreen MS Center

🇺🇸

Kirkland, Washington, United States

Wheaton Franciscan Healthcare - St. Francis Outpatient Center; Center for Neurological Disorders

🇺🇸

Milwaukee, Wisconsin, United States

IME - Instituto Médico Especializado

🇦🇷

Buenos Aires, Argentina

Centro de Especialidades Neurológicas y Rehabilitación - CENyR

🇦🇷

Buenos Aires, Argentina

CIER

🇦🇷

C. A. B. A., Argentina

Instituto de Investigaciones Metabolicas (Idim)

🇦🇷

Ciudad Autonoma de Buenos Aires, Argentina

Diagnostico Medico Oroño

🇦🇷

Rosario, Argentina

Cer San Juan

🇦🇷

San Juan, Argentina

Centro de Investigaciones Médicas Tucuman

🇦🇷

San Miguel de Tucuman, Argentina

Peking University First Hospital

🇨🇳

Beijing City, China

Beijing Tiantan Hospital,Capital Medical University

🇨🇳

Beijing, China

the First Hospital of Jilin University

🇨🇳

Changchun, China

Xiangya Hospital Central South University

🇨🇳

Changsha City, China

West China Hospital, Sichuan University

🇨🇳

Chengdu, China

The First Affiliated Hospital, Chongqing Medical University

🇨🇳

Chongqing, China

The First Affiliated Hospital of Sun Yat-sen University

🇨🇳

Guangzhou City, China

The second Affiliated Hospital of Guangzhou Medical University

🇨🇳

Guangzhou City, China

The affiliated Hospital of Guiyang Medical College

🇨🇳

Guiyang, China

The First People?s Hospital of Yunnan Province

🇨🇳

Kunming City, China

The Second Hospital of Hebei Medical University

🇨🇳

Shijiazhuang, China

The First Affiliated Hospital of Soochow University

🇨🇳

Suzhou City, China

1st Affiliated Hospital of Shanxi Medical University

🇨🇳

Taiyuan, China

Tianjin Medical University General Hospital

🇨🇳

Tianjin, China

Xinjiang People Hospital

🇨🇳

Urumqi City, China

Tongji Hospital Tongji Medical College Huazhong University of Science and Technology

🇨🇳

Wuhan City, China

Tangdu Hospital, The Fourth Military Medical University

🇨🇳

Xi'an, China

NeuroINC

🇩🇴

Santiago de los Caballeros, Dominican Republic

Hospital Padre Billini

🇩🇴

Santo Domingo, Dominican Republic

Helsinki University Central Hospital

🇫🇮

Helsinki, Finland

New Hospitals

🇬🇪

Tbilisi, Georgia

Pineo Medical Ecosystem

🇬🇪

Tbilisi, Georgia

St. Michael hospital

🇬🇪

Tbilisi, Georgia

MediClab Georgia

🇬🇪

Tbilisi, Georgia

Khechinashvili University Hospital

🇬🇪

Tbilisi, Georgia

Jüdisches Krankenhaus Berlin

🇩🇪

Berlin, Germany

Studienzentrum Dr. Bischof GmbH

🇩🇪

Böblingen, Germany

Universitätsklinikum "Carl Gustav Carus", Zentrum für Klinische Neurowissenschaften

🇩🇪

Dresden, Germany

Universitätsklinikum Gießen und Marburg GmbH

🇩🇪

Gießen, Germany

Uniklinik Schleswig-Holstein

🇩🇪

Kiel, Germany

Praxis Dr. med. Andreas Kowalik, Arzt für Neurologie und Psychiatrie

🇩🇪

Stuttgart, Germany

Universitätsklinikum Tübingen, Zentrum für Neurologie

🇩🇪

Tübingen, Germany

Universitätsklinikum Ulm

🇩🇪

Ulm, Germany

Pamela Youde Nethersole Eastern Hospital

🇭🇰

Hong Kong, Hong Kong

Prince of Wales Hospital

🇭🇰

Shatin, New Territories, Hong Kong

Clinexpert Kft.

🇭🇺

Budapest, Hungary

S-Medicon Egeszsegugyi Szolgaltato Kft.

🇭🇺

Budapest, Hungary

Markhot Ferenc Oktatokorhaz és Rendelointezet

🇭🇺

Eger, Hungary

Pest Megyei Flor Ferenc Korhaz

🇭🇺

Kistarcsa, Hungary

Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ

🇭🇺

Szeged, Hungary

AOU Seconda Università degli Studi

🇮🇹

Napoli, Campania, Italy

AOU Policlinico - Università L. Vanvitelli

🇮🇹

Napoli, Campania, Italy

A.O.U. di Parma

🇮🇹

Parma, Emilia-Romagna, Italy

Policlinico Tor Vergata Dip. Neuroscienze-Clinica Neurologica-UOSD Sclerosi Multipla

🇮🇹

Roma, Lazio, Italy

Policlinico Umberto I

🇮🇹

Roma, Lazio, Italy

Azienda Ospedaliera Sant'Andrea

🇮🇹

Roma, Lazio, Italy

ASST PAPA GIOVANNI XXIII Neurologia USS Malattie Autoimmuni Centro Sclerosi Multipla

🇮🇹

Bergamo, Lombardia, Italy

IRCCS Ospedale San Raffaele

🇮🇹

Milano, Lombardia, Italy

Ospedale Regina Montis Regalis

🇮🇹

Mondovì (CN), Piemonte, Italy

AO.U. Policlinico Riuniti Foggia

🇮🇹

Foggia, Puglia, Italy

AOU Policlinico V. Emanuele - P.O G. Rodolico

🇮🇹

Catania, Sicilia, Italy

Azienda Ospedaliera di Padova

🇮🇹

Padova, Veneto, Italy

Aga Khan University Hospital

🇰🇪

Nairobi, Kenya

Clinical Research Institute Saltillo

🇲🇽

Saltillo, Coahuila, Mexico

Health Pharma Professional Research

🇲🇽

Cdmx, Mexico CITY (federal District), Mexico

Grupo Medico de Investigacion Clinica Multidisciplinaria

🇲🇽

Mexico City, Mexico CITY (federal District), Mexico

Neurociencias Estudios Clinicos S.C.

🇲🇽

Culiacán, Sinaloa, Mexico

Hospital General de Mexico

🇲🇽

Mexico, Tlaxcala, Mexico

Zuyderland Medisch Centrum - Sittard Geleen

🇳🇱

Sittard-Geleen, Netherlands

PHO General City Hospital 8th September Center for dialysis

🇲🇰

Skopje, North Macedonia

University Clinic for Neurology - Skopje

🇲🇰

Skopje, North Macedonia

Clinical Hospital Stip

🇲🇰

Stip, North Macedonia

Hospital IV Alberto Sabogal Sologuren

🇵🇪

Bellavista, Peru

Hospital Nacional Guillermo Almenara Irigoyen

🇵🇪

La Victoria, Lima, Peru

Hospital Nacional Dos de Mayo

🇵🇪

Lima, Peru

Clinica Internacional Sede Lima

🇵🇪

LIma, Peru

Hospital Maria Auxiliadora

🇵🇪

Lima, Peru

Clinica Centenario Peruano Japonesa

🇵🇪

Pueblo Libre, Peru

ProNeuro Centrum Medyczne

🇵🇱

?ory, Poland

Neurocentrum Bydgoszcz sp. z o.o

🇵🇱

Bydgoszcz, Poland

Care Clinic

🇵🇱

Katowice, Poland

MT Medic Krosno

🇵🇱

Krosno, Poland

Centrum Neurologii Krzysztof Selmaj

🇵🇱

Lodz, Poland

Rodzinne Centrum Medyczne Lubimed.pl

🇵🇱

Lublin, Poland

Neurologiczny Niepubliczny ZOZ Centrum Leczenia SM Osrodek Bada? Klinicznych

🇵🇱

Plewiska, Poland

MedPolonia

🇵🇱

Poznan, Poland

Instytut Psychiatrii i Neurologii II Klinika Neurologiczna

🇵🇱

Warszawa, Poland

IBISMED Wielospecjalistyczne Centrum Medyczne

🇵🇱

Zabrze, Poland

Hospital Alvaro Cunqueiro

🇪🇸

Vigo, Pontevedra, Spain

Hospital Universitari Vall d'Hebron

🇪🇸

Barcelona, Spain

Hospital Universitario de la Princesa

🇪🇸

Madrid, Spain

Hospital General Universitario Gregorio Marañon

🇪🇸

Madrid, Spain

Hospital Ramon y Cajal

🇪🇸

Madrid, Spain

Fundacion Jimenez Diaz

🇪🇸

Madrid, Spain

Hospital Regional Universitario de Malaga ? Hospital General

🇪🇸

Malaga, Spain

Hospital Universitario Virgen Macarena

🇪🇸

Sevilla, Spain

Hospital de Braga

🇵🇹

Braga, Portugal

HUC

🇵🇹

Coimbra, Portugal

Hospital Santo Antonio dos Capuchos

🇵🇹

Lisboa, Portugal

Hospital da Luz

🇵🇹

Lisboa, Portugal

Hospital Geral de Santo Antonio

🇵🇹

Porto, Portugal

Hospital de Sao Joao

🇵🇹

Porto, Portugal

Centro Hospitalar Entre o Douro e Vouga E.P.E. - Hospital de São Sebastião

🇵🇹

Santa Maria Da Feira, Portugal

Republican clinical hospital named after G.G. Kuvatov

🇷🇺

UFA, Baskortostan, Russian Federation

Leningrad Regional Clinical Hospital

🇷🇺

St Petersburg, Sankt Petersburg, Russian Federation

Pavlov State Medical Uni

🇷🇺

St Petersburg, Sankt Petersburg, Russian Federation

Ulyanovsk Regional Clinical Hospital

🇷🇺

Ulyanovsk, Uljanovsk, Russian Federation

Center of Cardiology and Neurology

🇷🇺

Kirov, Russian Federation

FSBIH Siberian Regional Medical Centre of FMBA of Russia

🇷🇺

Novosibirsk, Russian Federation

University Clinical Center of Serbia

🇷🇸

Belgrade, Serbia

Hospital Universitari de Bellvitge

🇪🇸

L'Hospitalet de Llobregat, Barcelona, Spain

Hospital Quiron de Madrid

🇪🇸

Pozuelo de Alarcon, Madrid, Spain

Hospital Universitario Virgen de Arrixaca

🇪🇸

EL Palmar (EL Palmar), Murcia, Spain

Ams of Ukraine

🇺🇦

Kharkov, Ukraine

Lviv Regional Clinical Hospital

🇺🇦

Lviv, Ukraine

Odesa Regional Clinical Hospital

🇺🇦

Odesa, Ukraine

© Copyright 2025. All Rights Reserved by MedPath